news
Dec 14, 2021
Pfizer to acquire Arena Pharma; Takeda’s ‘Wave 2’ multiple myeloma med data; Novartis’s next-gen CAR-Ts clinical data; Roche unveils Avenio system
Pfizer acquires drugmaker Arena for USD 6.7 billion to address unmet needs Pfizer declared that it is acquiring Arena Pharmaceuticals, a drug company specializing in inflammation and immunology, for almost USD 7 billion. The pharma giant said it would finance the agreement, worth USD 6.7 billion, with cash on ha...
Read More...
Dec 09, 2021
Boston Scientific’s MODULAR CRM System; Restore Medical’s ContraBand clinical trial result; BD acquires Venclose; Roche differentiates mutations in Omicron; Linus’s StrandDx-ASD; HelioLiver launches liquid biopsy test
Boston Scientific initiates trial to evaluate industry's first Modular CRM System On December 02, 2021, Boston Scientific Corporation started the MODULAR ATP clinical trial to examine the safety, performance, and effectiveness of the mCRM™ Modular Therapy System. The system comprises of two cardiac ...
Read More...
Dec 07, 2021
Aslan Pharma – IQVIA collaboration; Reata’s kidney drug bardoxolone; Alzheimer’s Disease treatment update; Recordati to acquire EUSA
Aslan Pharmaceuticals enters into a strategic collaboration with IQVIA ASLAN Pharmaceuticals announced the appointment of IQVIA Biotech, a provider of analytics, technology solutions, and clinical research services to the life sciences industry, as its preferred clinical research organisation for log...
Read More...
Dec 02, 2021
LensGen’s Juvene Intraocular Lens; Nevro announces clinical data publications; FDA Clearance to Immunexpress’s SeptiCyte; GE unveils AI and Digital Technologies; Canon launches PIQE DLR and SilverBeam; Hyperfine’s Swoop gets FDA clearance
Canon Medical launches super-resolution deep-learning reconstruction for Cardiac CT scans On November 28, 2021, Canon Medical launched the Precise IQ Engine (PIQE) DLR and SilverBeam filter in the recent version of the Aquilion ONE / PRISM edition. PIQE, super-resolution deep-learning reconstruction techno...
Read More...
Nov 30, 2021
GE Healthcare-Optellum’s collaboration; Ocugen’s Covid-19 vaccine trial; Blueprint to acquire Lengo Therapeutics; Therapixel’s Mammoscreen
GE Healthcare, Optellum collaborate for AI-based lung cancer diagnosis GE Healthcare has collaborated with Optellum to progress precision diagnosis and lung cancer treatment with artificial intelligence. The partnership is zeroed in on helping healthcare providers to evaluate the malignancy of a lung nodule a...
Read More...
Nov 25, 2021
Neurent Medical’s NEUROMARK; Brain Navi NaoTrac received European CE Mark approval; Theradaptive receives Breakthrough Medical Device Designation; HAGAR GWave awarded Breakthrough Device Designation; Fujifilm launches ColoAssist PRO
Neurent Medical obtains FDA Clearance for NEUROMARK™, a novel multi-point Nerve Disruption Treatment for Chronic Rhinitis On November 18, 2021, Neurent Medical, a company working in developing treatments for chronic inflammatory sino-nasal diseases, received clearance from the Food and Drug Ad...
Read More...
Nov 23, 2021
Bluebird bio may get gene therapy approved in the US; Neurocrine pens $2.6B pact with Sosei Heptares; FDA opens clearances for hepatitis C diagnostics; Twist nabs antibody discovery biotech Abveris for $190M
Bluebird bio may finally get a gene therapy approved in the US Bluebird bio may get gene therapy approved in the US. The Cambridge, MA biotech declared that the FDA had accepted and given priority review for Zynteglo, its gene therapy for the rare blood disorder beta-thalassemia. The announcement sets up an expe...
Read More...
Nov 18, 2021
Abbott’s Pacemaker System; Ivantis’s Hydrus Microstent; Medtronic’s PillCam Small Bowel 3; ALung Technologies’s Hemolung; AppliedVR’s EaseVRx; J&J to split into two companies; OrthAlign’s Lantern® launch; LumiThera’s Light-based Theranostic
J&J intends to split into two companies, separating consumer products and pharmaceutical businesses On November 12, 2021, Johnson & Johnson announced its plans to split the Company’s Consumer Health business, forming a new publicly traded company. This will help the company create two global leaders tha...
Read More...
Nov 16, 2021
AstraZeneca-Moderna’s AZD8601 VEGF-A mRNA Trial; Wision AI gets CE Mark approval; Getinge acquires Verrix; LumiThera buys Diopsys
AstraZeneca, Moderna announces positive data of mRNA potential in heart failure patients Moderna, Inc., a biotechnology company is pioneering messenger RNA (mRNA) therapeutics and vaccines, declared positive data from the AstraZeneca-led Phase 2 (EPICCURE) study assessing the use of an mRNA therapeutic, wh...
Read More...
Nov 11, 2021
TecTraum’s pro2cool receives Breakthrough Device Designation; Vektor Obtains FDA Clearance for vMap; Medtronic’s TMVR system; Sight Sciences’s PRECISION Trial; Alcon to buy Ivantis; Philips to acquire Cardiologs
TecTraum’s pro2cool® receives FDA Breakthrough Device Designation for the Concussions treatment On November 03, 2021, TecTraum Inc., working to develop the world’s first point-of-care treatment for concussions, announced that the US Food and Drug Administration (FDA) has provided a Breakthrough Device to its f...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
